Nanox Imaging Ltd. (NASDAQ: NNOX) has entered into a distribution agreement with SOLME RC, S.A., a Costa Rica-based medical equipment distributor, to market and support the Nanox.ARC, a multi-source digital tomosynthesis system designed to expand access to 3D medical imaging. The agreement positions Nanox to penetrate a new market in Central America, following recent entries into Argentina and Peru, signaling a strategic push to broaden its footprint across Latin America.
Under the agreement, SOLME will oversee marketing, distribution, installation, training, and ongoing technical support for the Nanox.ARC in Costa Rica. SOLME is a registered supplier to the Caja Costarricense de Seguro Social (CCSS), the country's principal purchaser and provider of hospital services. This relationship could facilitate adoption within Costa Rica's public healthcare system, potentially accelerating the deployment of Nanox's technology to a broader patient population. Commercialization will proceed following applicable regulatory registration, which includes an initial six-month proof-of-concept device registration period before full registration. This phased approach allows for real-world evaluation and adaptation, which may smooth the path to full market approval.
The Nanox.ARC is a cost-effective, 3D multi-source digital tomosynthesis imaging system designed for ease of use and scalability. It is part of the Nanox ecosystem, which integrates affordable imaging hardware, AI-based solutions, cloud-based software, remote radiology, health IT solutions, and a marketplace to enable earlier detection, improved clinical efficiency, and broader access to care. By providing a seamless solution from scan to interpretation, Nanox aims to enhance the efficiency of routine imaging workflows, support early detection of disease, and improve patient outcomes.
Costa Rica represents Nanox's third Latin American market this year, following Argentina and Peru. This expansion underscores the company's commitment to driving the world's transition to preventive health care by lowering barriers to adoption and improving utilization. The move into Costa Rica could serve as a model for other markets in the region, where access to advanced medical imaging is often limited. By partnering with a local distributor that has established ties to the national healthcare system, Nanox may overcome logistical and regulatory hurdles more efficiently.
The implications of this announcement extend beyond mere market expansion. Nanox's vision is to expand the reach of medical imaging both within and beyond traditional hospital settings. In Costa Rica, where the CCSS dominates hospital services, the agreement could lead to earlier detection of diseases and more efficient use of healthcare resources. The proof-of-concept period will be critical to demonstrate the system's value in a real-world setting, potentially influencing broader adoption across Latin America. For investors, this agreement signals progress in Nanox's commercialization strategy, though full revenue impact will depend on regulatory approvals and subsequent adoption rates. To view the full press release, visit https://ibn.fm/C77lJ. The latest news and updates relating to NNOX are available in the company's newsroom at http://ibn.fm/NNOX. For more information about BioMedWire, visit https://www.BioMedWire.com.
